DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data.
暂无分享,去创建一个
J. Koropatnick | J. Barrett | J. Mymryk | A. Nichols | Saman Maleki Vareki | F. Ghasemi | Steven F. Gameiro | S. Maleki Vareki
[1] S. M. Vareki. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors , 2018 .
[2] Y. Samuels,et al. Cancer research in the era of immunogenomics , 2018, ESMO Open.
[3] M. Dhodapkar,et al. Checkpoint Inhibition in Myeloma: Opportunities and Challenges , 2018, Front. Immunol..
[4] X. Liu,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[5] E. King,et al. Pan-cancer deconvolution of tumour composition using DNA methylation , 2018, Nature Communications.
[6] J. Koropatnick,et al. Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy , 2018, Oncoimmunology.
[7] B. Fox,et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors , 2018, Nature Communications.
[8] I. Hellstrom,et al. Tumor Regression and Cure Depends on Sustained Th1 Responses , 2018, Journal of immunotherapy.
[9] M. Fehlings,et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates , 2018, Nature.
[10] Adrian V. Lee,et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.
[11] Peter W. Laird,et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.
[12] Steven J. M. Jones,et al. The Immune Landscape of Cancer , 2018, Immunity.
[13] Z. Trajanoski,et al. Quantifying tumor-infiltrating immune cells from transcriptomics data , 2018, Cancer Immunology, Immunotherapy.
[14] Matthew Collin,et al. Human dendritic cell subsets: an update , 2018, Immunology.
[15] Edmond Sabo,et al. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma , 2018, Medical Oncology.
[16] G. Belz,et al. Natural killer cells and anti-tumor immunity. , 2017, Molecular immunology.
[17] N. Pochet,et al. Transcriptional signature of human pro-inflammatory TH17 cells identifies reduced IL10 gene expression in multiple sclerosis , 2017, Nature Communications.
[18] M. Zaidi,et al. TAMeless traitors: macrophages in cancer progression and metastasis , 2017, British Journal of Cancer.
[19] W. Guo,et al. Elevated Th22 cells and related cytokines in patients with epithelial ovarian cancer , 2017, Medicine.
[20] G. Freeman,et al. Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. , 2017, Cancer cell.
[21] J. Barrett,et al. Analysis of Class I Major Histocompatibility Complex Gene Transcription in Human Tumors Caused by Human Papillomavirus Infection , 2017, Viruses.
[22] L. Emens. Breast Cancer Immunotherapy: Facts and Hopes , 2017, Clinical Cancer Research.
[23] J. Torchia,et al. Human papillomavirus dysregulates the cellular apparatus controlling the methylation status of H3K27 in different human cancers to consistently alter gene expression regardless of tissue of origin , 2017, Oncotarget.
[24] Tinghua Cao,et al. RORγt and RORα signature genes in human Th17 cells , 2017, PloS one.
[25] Laurence Zitvogel,et al. The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.
[26] D. Fisher,et al. Immune and molecular correlates in melanoma treated with immune checkpoint blockade , 2017, Cancer.
[27] I. Wistuba,et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer , 2017, Nature Medicine.
[28] D. Farber,et al. Dendritic Cells Display Subset and Tissue‐Specific Maturation Dynamics over Human Life , 2017, Immunity.
[29] S. Carter,et al. Loss of PTEN Is Associated with Resistance to Anti‐PD‐1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma , 2017, Immunity.
[30] Alberto Mantovani,et al. Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.
[31] Pornpimol Charoentong,et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.
[32] B. Ruffell,et al. Dendritic Cells and Cancer Immunity. , 2016, Trends in immunology.
[33] Patrick Danaher,et al. Gene expression markers of Tumor Infiltrating Leukocytes , 2016, Journal of Immunotherapy for Cancer.
[34] E. Elkord,et al. Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting , 2016, Vaccines.
[35] Jordan Anaya,et al. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs , 2016, PeerJ Comput. Sci..
[36] J. Aguillón,et al. Gene Expression Profiling of Human Monocyte-derived Dendritic Cells – Searching for Molecular Regulators of Tolerogenicity , 2015, Front. Immunol..
[37] Jian Huang,et al. Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis , 2015, PloS one.
[38] P. Klenerman,et al. CD39 Expression Identifies Terminally Exhausted CD8+ T Cells , 2015, PLoS pathogens.
[39] A. Koch,et al. MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data , 2015, BMC Genomics.
[40] F. Gao,et al. Th22 cell accumulation is associated with colorectal cancer development. , 2015, World journal of gastroenterology.
[41] M. Kaplan,et al. The development and in vivo function of T helper 9 cells , 2015, Nature Reviews Immunology.
[42] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[43] M. Smyth,et al. Balancing natural killer cell activation through paired receptors , 2015, Nature Reviews Immunology.
[44] P. Validire,et al. CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients , 2015, The Journal of Immunology.
[45] F. Végran,et al. Th9 Cells: a Novel Cd4 T-cell Subset in the Immune War against Cancer the Role of Cd4 T-cell Polarization in Cancer the Biology of Th9 Cells the Mechanism of the Antitumor Effects of Th9 Future Direction and Concluding Remarks , 2022 .
[46] N. Hacohen,et al. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.
[47] S. Mehrotra,et al. Th17 Cells in Cancer: The Ultimate Identity Crisis , 2014, Front. Immunol..
[48] Chester Ni,et al. Identification of a specific gene signature in human Th1/17 cells (BA13P.126) , 2014, Journal of Immunology.
[49] Xin Wang,et al. Role of high expression of IL-9 in prognosis of CLL. , 2014, International journal of clinical and experimental pathology.
[50] Y. Natkunam,et al. Expression of the activating receptor, NKp46 (CD335), in human natural killer and T-cell neoplasia. , 2013, American journal of clinical pathology.
[51] M. Kaplan,et al. Th9 cell development requires a BATF-regulated transcriptional network. , 2013, The Journal of clinical investigation.
[52] Z. Trajanoski,et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.
[53] H. Schreiber,et al. Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.
[54] G. Coukos,et al. CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor , 2013, Clinical Cancer Research.
[55] A. Bovier,et al. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? , 2013, Nature Reviews Cancer.
[56] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[57] I. Ellis,et al. CD8+ T lymphocytes infiltrating breast cancer , 2012, Oncoimmunology.
[58] K. Oestreich,et al. Transcriptional mechanisms that regulate T helper 1 cell differentiation. , 2012, Current opinion in immunology.
[59] B. Xia,et al. CD4+T Cells: Differentiation and Functions , 2012, Clinical & developmental immunology.
[60] K. Gunderson,et al. High density DNA methylation array with single CpG site resolution. , 2011, Genomics.
[61] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[62] G. D. de Bock,et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.
[63] G. Hill,et al. CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis , 2011, Proceedings of the National Academy of Sciences.
[64] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[65] Zlatko Trajanoski,et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] J. Fechner,et al. An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells , 2010, The Journal of Immunology.
[67] S. Durham,et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. , 2009, The Journal of clinical investigation.
[68] L. Coussens,et al. Polarized immune responses differentially regulate cancer development , 2008, Immunological reviews.
[69] Edgar Erdfelder,et al. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences , 2007, Behavior research methods.
[70] V. Reuter,et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma , 2007, Proceedings of the National Academy of Sciences.
[71] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[72] P. Lipponen,et al. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. , 2005, Anticancer research.
[73] T. Schumacher,et al. On the Role of Melanoma-Specific CD8+ T-Cell Immunity in Disease Progression of Advanced-Stage Melanoma Patients , 2004, Clinical Cancer Research.
[74] Akiko Kikuchi-Maki,et al. NKp44 Triggers NK Cell Activation through DAP12 Association That Is Not Influenced by a Putative Cytoplasmic Inhibitory Sequence 1 , 2004, The Journal of Immunology.
[75] T. Oshikiri,et al. CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.
[76] B. Plougastel,et al. Immune functions encoded by the natural killer gene complex , 2003, Nature Reviews Immunology.
[77] D. Munn,et al. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division , 2002, Immunology.
[78] G. Damonte,et al. Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase , 2002, The Journal of experimental medicine.
[79] A. Borrie,et al. T Lymphocyte-Based Cancer Immunotherapeutics. , 2018, International review of cell and molecular biology.
[80] K. Kinzler,et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.